Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism

Area of Science:

• Oncology
• Hematology
• Immunotherapy

Background:

• CD30 is overexpressed in various T-cell lymphomas (TCL), including peripheral T-cell lymphomas (PTCL) and cutaneous T-cell lymphomas (CTCL).
• Brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, is approved for relapsed/refractory (R/R) systemic anaplastic large cell lymphoma (sALCL) and specific cutaneous T-cell lymphomas (CTCL).
• Disease progression after BV monotherapy necessitates investigation into effective combination therapies.

Purpose of the Study:

• To review the combination applications of brentuximab vedotin (BV) in T-cell lymphomas (TCL).
• To highlight ongoing studies and future directions for BV combination therapies.
• To analyze the mechanisms of BV action and resistance in TCL.

Main Methods:

• Review of clinical studies and literature on brentuximab vedotin (BV) combination therapies.
• Analysis of a phase III clinical study comparing BV with cyclophosphamide, doxorubicin, and prednisone (CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for CD30-positive PTCL.
• Discussion of underlying mechanisms of BV and T-cell lymphoma (TCL) resistance.

Main Results:

• The combination of BV with CHP demonstrated superiority over CHOP for CD30-positive PTCL.
• BV plus CHP is now approved as a first-line therapy for CD30-positive PTCL (sALCL in Europe).
• Encouraging results from various BV combination studies are summarized.

Conclusions:

• Brentuximab vedotin (BV) combination therapies offer promising treatment strategies for T-cell lymphomas (TCL).
• Understanding BV's mechanisms and resistance pathways is crucial for optimizing future therapeutic applications.
• Further research into BV combinations holds potential for improved patient outcomes in CD30-positive TCL.